Corvus Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Corvus Pharmaceuticals es Rick Miller , nombrado en Feb 2014, tiene una permanencia de 10.75 años. compensación anual total es $1.32M, compuesta por 8.3% salario y 91.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.82% de las acciones de la empresa, por valor de $16.88M. La antigüedad media del equipo directivo y de la junta directiva es de 4.9 años y 9.5 años, respectivamente.
Información clave
Rick Miller
Chief Executive Officer (CEO)
US$1.3m
Compensación total
| Porcentaje del salario del CEO | 8.3% |
| Permanencia del CEO | 10.8yrs |
| Participación del CEO | 2.8% |
| Permanencia media de la dirección | 4.9yrs |
| Promedio de permanencia en la Junta Directiva | 9.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Sep 02Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$23m |
| Mar 31 2024 | n/a | n/a | -US$25m |
| Dec 31 2023 | US$1m | US$110k | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$524k | US$300k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$905k | US$300k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$1m | US$300k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$48m |
| Dec 31 2019 | US$1m | US$300k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$1m | US$300k | -US$47m |
| Sep 30 2018 | n/a | n/a | -US$48m |
| Jun 30 2018 | n/a | n/a | -US$51m |
| Mar 31 2018 | n/a | n/a | -US$54m |
| Dec 31 2017 | US$1m | US$302k | -US$56m |
Compensación vs. Mercado: La compensación total de Rick($USD1.32M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.34M).
Compensación vs. Ingresos: La compensación de Rick ha aumentado mientras la empresa no es rentable.
CEO
Rick Miller (73 yo)
10.8yrs
Permanencia
US$1,321,351
Compensación
Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 10.8yrs | US$1.32m | 2.82% $ 16.9m | |
| Co-Founder & Independent Director | no data | US$95.35k | sin datos | |
| Chief Financial Officer | 10yrs | US$660.76k | 0.45% $ 2.7m | |
| Senior Vice President of Pharmaceutical Development | 4.9yrs | US$616.26k | 0.25% $ 1.5m | |
| Senior Vice President of Research | 2.3yrs | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos |
4.9yrs
Permanencia media
67yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CRVS se considera experimentado (4.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 10.8yrs | US$1.32m | 2.82% $ 16.9m | |
| Co-Founder & Independent Director | 10yrs | US$95.35k | sin datos | |
| Independent Director | 10yrs | US$101.35k | sin datos | |
| Independent Director | 5.8yrs | US$97.35k | 0.016% $ 95.6k | |
| Independent Director | 7.8yrs | US$93.35k | sin datos | |
| Independent Director | 8.9yrs | US$109.35k | sin datos |
9.5yrs
Permanencia media
66.5yo
Promedio de edad
Junta con experiencia: La junta directiva de CRVS se considera experimentada (9.5 años de antigüedad promedio).